281 related articles for article (PubMed ID: 19106732)
1. Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes.
Clarke PM; Hayes AJ; Glasziou PG; Scott R; Simes J; Keech AC
Med Care; 2009 Jan; 47(1):61-8. PubMed ID: 19106732
[TBL] [Abstract][Full Text] [Related]
2. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.
Glasziou P; Alexander J; Beller E; Clarke P;
Health Qual Life Outcomes; 2007 Apr; 5():21. PubMed ID: 17462100
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
Hiukka A; Westerbacka J; Leinonen ES; Watanabe H; Wiklund O; Hulten LM; Salonen JT; Tuomainen TP; Yki-Järvinen H; Keech AC; Taskinen MR
J Am Coll Cardiol; 2008 Dec; 52(25):2190-7. PubMed ID: 19095138
[TBL] [Abstract][Full Text] [Related]
4. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
Carrington M; Stewart S
Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
[TBL] [Abstract][Full Text] [Related]
5. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
6. Preoperative cardiac risk index predicts long-term mortality and health status.
Hoeks SE; op Reimer WJ; van Gestel YR; Smolderen KG; Verhagen H; van Domburg RT; van Urk H; Poldermans D
Am J Med; 2009 Jun; 122(6):559-65. PubMed ID: 19376487
[TBL] [Abstract][Full Text] [Related]
7. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
[TBL] [Abstract][Full Text] [Related]
8. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure.
Smooke S; Horwich TB; Fonarow GC
Am Heart J; 2005 Jan; 149(1):168-74. PubMed ID: 15660049
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study.
Buyken AE; von Eckardstein A; Schulte H; Cullen P; Assmann G
Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):230-6. PubMed ID: 17446801
[TBL] [Abstract][Full Text] [Related]
10. The impact of Type 2 diabetes and microalbuminuria on future cardiovascular events in patients with clinically manifest vascular disease from the Second Manifestations of ARTerial disease (SMART) study.
Soedamah-Muthu SS; Visseren FL; Algra A; van der Graaf Y;
Diabet Med; 2008 Jan; 25(1):51-7. PubMed ID: 18199132
[TBL] [Abstract][Full Text] [Related]
11. Responsiveness of EQ-5D utility indices in alcohol-dependent patients.
Günther OH; Roick C; Angermeyer MC; König HH
Drug Alcohol Depend; 2008 Jan; 92(1-3):291-5. PubMed ID: 17888587
[TBL] [Abstract][Full Text] [Related]
12. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
13. Prediction of mortality in type 2 diabetes from health-related quality of life (ZODIAC-4).
Kleefstra N; Landman GW; Houweling ST; Ubink-Veltmaat LJ; Logtenberg SJ; Meyboom-de Jong B; Coyne JC; Groenier KH; Bilo HJ
Diabetes Care; 2008 May; 31(5):932-3. PubMed ID: 18319325
[TBL] [Abstract][Full Text] [Related]
14. Perceived mental health at the start of dialysis as a predictor of morbidity and mortality in patients with end-stage renal disease (CALVIDIA Study).
López Revuelta K; García López FJ; de Alvaro Moreno F; Alonso J
Nephrol Dial Transplant; 2004 Sep; 19(9):2347-53. PubMed ID: 15252167
[TBL] [Abstract][Full Text] [Related]
15. History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis.
Tanaka Y; Joki N; Hase H
Nephrol Dial Transplant; 2007 Oct; 22(10):2917-23. PubMed ID: 17644817
[TBL] [Abstract][Full Text] [Related]
16. Danish EQ-5D population norms.
Sørensen J; Davidsen M; Gudex C; Pedersen KM; Brønnum-Hansen H
Scand J Public Health; 2009 Jul; 37(5):467-74. PubMed ID: 19535407
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Steiner G
Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
[TBL] [Abstract][Full Text] [Related]
19. Low health-related quality of life is associated with all-cause mortality in patients with diabetes on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study.
Hayashino Y; Fukuhara S; Akiba T; Akizawa T; Asano Y; Saito S; Kurokawa K
Diabet Med; 2009 Sep; 26(9):921-7. PubMed ID: 19719714
[TBL] [Abstract][Full Text] [Related]
20. Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study.
Cui J; Forbes A; Kirby A; Simes J; Tonkin A
Eur J Cardiovasc Prev Rehabil; 2009 Dec; 16(6):660-8. PubMed ID: 19738473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
